26355-87-3

Upstream product

• 98-88-4 benzoyl chloride 
• 51806-98-5 2-aminopropanenitrile 
• 93-97-0 benzoic acid anhydride 
• 33898-53-2 2-cyanoaziridine 
• 103-71-9 phenyl isocyanate 
• 2198-64-3 N-benzoyl-L-alanine 
• 13313-25-2 N-benzoylethyleneimine 
• 19158-51-1 P-toluenesulfonyl cyanide 

Downstream Products

• 93690-98-3 N-benzoyl-L-thioalanine amide 
• 94208-94-3 N-[1-(4-phenyl-thiazol-2-yl)-ethyl]-benzamide 
• 94208-94-3 N-[(S)-1-(4-phenyl-thiazol-2-yl)-ethyl]-benzamide 
• 92580-55-7 2-((S)-1-benzoylamino-ethyl)-thiazole-4-carboxylic acid ethyl ester 
• 1249834-47-6 4-methyl-2-phenylthiazol-5-amine 
• 99087-39-5 N-benzoyl-DL-alanine ethyl dithioester 
• 26355-94-2 benzylidene-(4-methyl-2-phenyl-oxazol-5-yl)-amine 
• 26355-95-3 (4-methyl-2-phenyl-oxazol-5-yl)-(4-nitro-benzylidene)-amine 
• 13313-25-2 N-benzoylethyleneimine 

Relevant academic research and scientific papers

Cobalt-catalyzed hydrocyanation and hydroarylation of enamines

A mild, general and efficient hydrocyanation and hydroarylation of enamines catalyzed by Co(salen) complexes are described. Both reactions include regioselective C[sbnd]H bond formation of enamines, and the corresponding products are obtained in high yield. Hydroarylation critically discriminates the benzyl and benzoyl aromatic rings on nitrogen in cyclization step, and the corresponding isoindolinones including quaternary carbons are exclusively given.

PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Liposomal imexon

Disclosed are novel compositions comprising a lipid and imexon or a derivative thereof. Also disclosed are liposomal compositions comprising imexon or a derivative thereof. Methods for administrating pharmaceutically acceptable compositions comprising a lipid and imexon or a derivative thereof for the treatment of diseases, such as cancer, are also disclosed herein.

Cyanoaziridines for treating cancer

The present invention is directed to novel anti-cancer compounds of the formula. wherein X is CN, R4is hydrogen or lower alkyl; and R5is lower alkyl, lower cycloalkyl, alkenyl, alkynyl, aryl, monosubstituted aryl, disubstituted aryl,

The structure and resonance Raman spectra-structure correlations for N-benzoyl-DL-alanine ethyl dithioester

An X-ray crystallographic analysis of N-benzoyl-DL-alanine ethyl dithioester demonstrates that it takes up a B-type conformation comparable to that found for N-acylglycine dithioesters in the crystalline state.B-conformations are characterized by small N-